Noom Med Reviews Tirzepatide
Available first-line on the same asynchronous pathway as semaglutide. Given tirzepatide's efficacy advantage, expect member preference to pull volume here once it is offered without a cost hierarchy.
Sold as Zepbound, Mounjaro · Reviewed September 19, 2026
What “First-line” means here
Prescribed as a first-line option. No lower-cost trial is required before a member can start.
The pairing
How Noom Med handles Tirzepatide
These are the vendor-specific mechanics that determine what this molecule actually costs you and whether members stay on it long enough to benefit.
- Access status
- First-line
- Gating
- BMI ≥ 27. No step therapy.
- Prescribes directly
- Yes
- Step therapy
- No
- Prior authorization
- No
- Titration protocol
- Asynchronous-first with NP review; synchronous visits available on request
- Off-ramp
- Behavioral maintenance track carried over from the consumer product
- Care team
- Nurse practitioners, Physician oversight, Behavioral coaches
Ask Noom Med this
What share of new starts are choosing tirzepatide over semaglutide, and what does that mix do to your projected PMPM in year two?
Watch out
High enrollment is a cost risk, not just a win. Model what happens if uptake lands at the top of Noom's range.
The molecule
Tirzepatide in one page
The dual-incretin agent producing the largest average weight reductions recorded in this class. Higher efficacy, comparable cost, and rapidly growing share of employer spend.
Clinical profile
- Drug class
- Dual GIP/GLP-1 receptor agonist
- Brand names
- Zepbound — Chronic weight managementMounjaro — Type 2 diabetes
- Mechanism
- Agonizes both GIP and GLP-1 receptors. The dual mechanism is the accepted explanation for its efficacy advantage over single-agonist GLP-1s, though the relative contribution of GIP remains debated.
- Administration
- Once-weekly subcutaneous injection.
- Titration
- Initiated at a low weekly dose with escalation approximately every four weeks. The full ladder to the highest maintenance dose runs longer than semaglutide's, extending the window in which members are on drug but not yet at target.
- Typical result
- In registrational trials, average body-weight reduction of roughly a fifth of starting weight at about 72 weeks at higher doses — the highest reported in this class. Real-world persistence gaps apply here as they do everywhere.
- Generic available
- No
Known side effects
- Gastrointestinal effects broadly similar to other incretin agents, again concentrated in escalation
- Gallbladder events and pancreatitis reported at low rates
- Class boxed warning regarding thyroid C-cell tumors observed in rodents
- Lean-mass loss proportional to the larger total reduction, which matters more at this efficacy level
What benefits teams need to know
Higher efficacy is not automatically better economics
Greater average reduction at similar unit cost improves cost per point of weight lost. It also increases the likelihood members stay on therapy longer, which raises total spend. Model both effects; vendors will only show you the first.
Longer titration extends your exposure
A longer escalation ladder means more months of spend before a member reaches maintenance. If your program has a continuation-review gate, make sure the review point is set against this molecule's actual timeline rather than semaglutide's.
Lean mass deserves more attention here
Larger total weight reduction means larger absolute lean-mass loss. Vendors with real protein and resistance-training protocols matter more on this molecule than on lower-efficacy agents, particularly in older populations.
Alternatives
Other vendors and Tirzepatide
Same molecule, materially different access rules. The status column is where the cost difference lives.
| Vendor | Access | Score | PMPM |
|---|---|---|---|
| Virta Health Metabolic specialist | Escalation only | 8.7 | $40–$95 |
| Omada Health Coaching companion | Companion support | 8.4 | $32–$58 |
| Form Health Full-service clinical | First-line | 8.0 | $58–$105 |
| Twin Health Metabolic specialist | Escalation only | 7.8 | $55–$120 |
| Found Full-service clinical | Escalation only | 7.6 | $45–$85 |
| Vida Health Full-service clinical | Escalation only | 7.5 | $38–$78 |
Same vendor
Noom Med across the formulary
How this vendor positions each molecule tells you more about its cost discipline than any single review does.
First-line, with asynchronous-first intake and nurse-practitioner review. The low-friction pathway that drives Noom's category-leading enrollment also removes most of the brakes on initiation.
Present in the formulary but not a meaningful gate. Noom's model does not depend on routing members through it before incretin therapy.